Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: NAT10 promotes liver lipogenesis in mouse through N4-acetylcytidine modification of Srebf1 and Scap mRNA

Fig. 2

NAT10 improves AML12 cells lipogenesis and mRNA ac4C modification. (A) Overexpressing or silencing of NAT10 promoted or inhibited AML12 cell lipid droplets form (Oil red O staining, scale bar = 50 μm), (B) cellular FFA content, (C) Srebf1, (D) Acaca, (E) Fasn mRNA and (F) protein including Cd36 expression after AML12 were intervened with 150µmol/L PA. (G) Knockdown of NAT10 decreased mRNA ac4C modification in AML12 cells. (H) 20µmol/L Remodelin inhibited AML12 cellular lipid droplet forms (Oil red O staining, scale bar = 50 μm), (I) cellular FFA content, (J) Srebf1, Acaca and Fasn mRNA and (K) protein including Cd36 expression. Data were represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X